Alvimopan: A peripherally acting mu-opioid receptor antagonist

Drugs of Today

Volumn 43, Issue 9, 2007, Pages 611-625

  Leslie, John B ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVIMOPAN; LAXATIVE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; OPIATE; PLACEBO;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG STRUCTURE; ENTEROPATHY; FEVER; GASTROINTESTINAL MOTILITY; HUMAN; HYPERTENSION; ILEUS; NAUSEA; POSTOPERATIVE COMPLICATION; REVIEW; SINGLE DRUG DOSE; VOMITING; WOUND INFECTION;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; PIPERIDINES; POSTOPERATIVE COMPLICATIONS; RECEPTORS, OPIOID, MU;

EID: 35548978089     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.9.1086176     Document Type: Review

References (74)

1. Quigley, C. The role of opioids in cancer pain. BMJ 2005, 331: 825-9.
2. Kalso, E., Edwards, J.E., Moore, R.A., McQuay, H.J. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 2004, 112: 372-80.
3. Leslie, J.B. Alvimopan for the management of postoperative ileus. Ann Pharmacother 2005, 39: 1502-10.
4. Kurz, A., Sessler, D.I. Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs 2003, 63: 649-71.
5. Thorpe, D.M. Management of opioid-induced constipation. Curr Pain Headache Rep 2001, 5: 237-40.
6. Delaney, C., Kehlet, H., Senagore, A., et al. Postoperative ileus: Profiles, risk factors, and definitions - a framework for optimizing surgical outcomes in patients undergoing major abdominal and colorectal surgery. In: Bosker, G. (Ed.). Clinical Consensus Update in General Surgery. Pharmatecture, LLC, Roswell 2006. Available at: http://www.clinicalwebcasts.com/updates/index. htm. Accessed March 2007.
7. Liu, M., Wittbrodt, E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002, 23: 48-53.
8. Delaney, C.P., Weese, J.L., Hyman, N.H. et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005, 48: 1114-25; discussion 1125-6; author reply 1127-9.
9. Leslie, J.B., Steinbrook, R.A., Viscusi, E., Du, W., Techner, L. Alvimopan oral dosing 30 to 90 minutes before and twice daily after bowel resection accelerates GI recovery. Anesthesiol 2006, 105: A122.
10. Büchler, M.W., Monson, J.R.T., Flamant, Y. et al. Recovery of gastrointestinal function following bowel resection: Results of a European double-blind, randomized, placebo-controlled study and comparison with US experience. Dis Colon Rectum 2006, 49: 748.
11. Viscusi, E.R., Goldstein, S., Witkowski, T. et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: Results of a randomized, double- blind, controlled study. Surg Endosc 2006, 20: 64-70.
12. Wolff, B.G., Michelassi, F., Gerkin, T.M. et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004, 240: 728-34; discussion 734-5.
13. Adolor press release. GlaxoSmithKline and Adolor report top-line results from phase 3 studies of alvimopan. Available at: http://www.adolor.com/press_news.php. Accessed September 11, 2006.
14. Morlion, B., Aggarwal, N., Frank, L., Rentz, A., Kleoudis, C., Bell, T.J. Efficacy of alvimopan, a peripheral opioid receptor antagonist, for the management of gastrointestinal adverse events (GIAEs) associated with opioid use: Assessment using the PAC-SYM questionnaire. Annual Meeting of the American Pain Society, San Antonio 2006, Poster 933.
15. Morlion, B., Jansen, J.P., Sabatowski, R. et al. Symptom relief correlates with global improvement of opioid-induced gastrointestinal side effects: Results from an alvimopan study in non-cancer pain (SB-7670905/011). 5th Congress of the European Federation of International Association for the Study of Pain, Istanbul 2006, Poster 176.
16. Tark, M., Sabatowski, R., Frank, L., Rentz, A., Kleoudis, C., Bell, T.J. Effect of alvimopan, a peripheral opioid receptor antagonist, on health-related quality of life (HRQOL) in patients who develop gastrointestinal adverse events (GIAEs) while taking opioids for persistent non-cancer pain. Annual Meeting of the American Pain Society, San Antonio 2006, Poster 945.
17. Webster, L., Jansen, J.P., Peppin, J. et al. A randomized, double-blind, placebo-controlled, multicenter, phase IIb study to evaluate the efficacy and safety of multiple alvimopan dosage regimens for the treatment of gastrointestinal adverse events associated with opioid use in subjects with persistent non-cancer pain (SB-767905/011). Annual Meeting of the American Pain Society, San Antonio 2006, Poster 761.
18. Luckey, A., Livingston, E., Tache, Y. Mechanisms and treatment of postoperative ileus. Arch Surg 2003, 138: 206-14.
19. Yuan, C.S., Foss, J.F., O'Connor, M. et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA 2000, 283: 367-72.
20. Yuan, C.S., Wei, G., Foss, J.F., O'Connor, M., Karrison, T., Osinski, J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: A double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 2002, 300: 118-23.
21. Foss, J.F. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 2001, 182: 19S-26.
22. Pappagallo, M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001, 182: 11S-8S.
23. Duthie, D.J., Nimmo, W.S. Adverse effects of opioid analgesic drugs. Br J Anaesth 1987, 59: 61-77.
24. Glare, P., Lickiss, J.N. Unrecognized constipation in patients with advanced cancer: A recipe for therapeutic disaster. J Pain Symptom Manage 1992, 7: 369-71.
25. Mancini, I., Bruera, E. Constipation in advanced cancer patients. Support Care Cancer 1998, 6: 356-64.
26. McNicol, E., Horowicz-Mehler, N., Fisk, R.A. et al. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain 2003, 4: 231-56.
27. Panchal, S.J., Anghelescu, D.L., Benedetti, C. et al. Clinical practice guidelines in oncology: Adult cancer pain. National Comprehensive Cancer Network. Available at: http://www.nc-cn.org. Accessed December 5, 2006.
28. Behm, B., Stollman, N. Postoperative ileus: Etiologies and interventions. Clin Gastroenterol Hepatol 2003, 1: 71-80.
29. Kehlet, H., Holte, K. Review of postoperative ileus. Am J Surg 2001, 182 (Suppl.): 3S-10.
30. Chang, S.S., Baumgartner, R.G., Wells, N., Cookson, M.S., Smith, J.A. Jr. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol 2002, 167: 208-11.
31. Kariv, Y., Wang, W., Senagore, A.J., Hammel, J.P., Fazio, V.W., Delaney, C.P. Multivariable analysis of factors associated with hospital readmission after intestinal surgery. Am J Surg 2006, 191: 364-71.
32. Kalff, J.C., Schraut, W.H., Simmons, R.L., Bauer, A.J. Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg 1998, 228: 652-63.
33. Lundgren, O. Sympathetic input into the enteric nervous system. Gut 2000, 47 (Suppl. 4): iv33-5; discussion iv36.
34. Costa, M., Brookes, S.J., Hennig, G.W. Anatomy and physiology of the enteric nervous system. Gut 2000, 47 (Suppl. 4): iv15-9; discussion iv26.
35. Wood, J.D., Alpers, D.H., Andrews, P.L. Fundamentals of neurogastroenterology. Gut 1999, 45 (Suppl. 2): II6-II16.
36. Davis, M.P. The opioid bowel syndrome: A review of pathophysiology and treatment. J Opioid Manag 2005, 1: 153-61.
37. Holzer, P. Opioids and opioid receptors in the enteric nervous system: From a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004, 361: 192-5.
38. Sanger, G.J., Holzer, P. Endogenous opioids and the gastrointestinal tract. Semin Colon Rectal Surg 2005, 16: 197-9.
39. Sternini, C., Patierno, S., Selmer, I.S., Kirchgessner, A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004, 16 (Suppl. 2): 3-16.
40. Gonenne, J., Camilleri, M., Ferber, I. et al. Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study. Clin Gastroenterol Hepatol 2005, 3: 784-91.
41. Basse, L., Raskov, H.H., Hjort Jakobsen, D. et al. Accelerated postoperative recovery programme after colonic resection improves physical performance, pulmonary function and body composition. Br J Surg 2002, 89: 446-53.
42. Delaney, C.P., Fazio, V.W., Senagore, A.J., Robinson, B., Halverson, A.L., Remzi, F.H. 'Fast track' postoperative management protocol for patients with high co-morbidity undergoing complex abdominal and pelvic colorectal surgery. Br J Surg 2001, 88: 1533-8.
43. Delaney, C.P., Senagore, A.J., Viscusi, E.R. et al. Postoperative upper and lower gastrointestinal recovery and gastrointestinal morbidity in patients undergoing bowel resection: Pooled analysis of placebo data from 3 randomized controlled trials. Am J Surg 2006, 191: 315-9.
44. Kehlet, H. Preventive measures to minimize or avoid postoperative ileus. Semin Colon Rectal Surg 2005, 16: 203-6.
45. Kehlet, H., Dahl, J.B. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet 2003, 362: 1921-8.
46. Kehlet, H., Kennedy, R.H. Laparoscopic colonic surgery - mission accomplished or work in progress? Colorectal Dis 2006, 8: 514-7.
47. Mukherjee, A., Senagore, A.J., Delaney, C.P. Postoperative care pathways. Semin Colon Rectal Surg 2005, 16: 215-27.
48. Person, B., Wexner, S.D. The management of postoperative ileus. Curr Probl Surg 2006, 43: 6-65.
49. Holte, K., Kehlet, H. Postoperative ileus: Progress towards effective management. Drugs 2002, 62: 2603-15.
50. Liu, S.S., Hodgson, P.S., Carpenter, R.L., Fricke, J.R. Jr. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 2001, 69: 66-71.
51. Zimmerman, D.M., Gidda, J.S., Cantrell, B.E., Schoepp, D.D., Johnson, B.G., Leander, J.D. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem 1994, 37: 2262-5.
52. Viscusi, E.R., Rathmell, J., Fichera, A., Gan, T.J., Israel, R.J. A double-blind, randomized, placebo-controlled trial of methylnaltrexone (MNTX) for post-operative bowel dysfunction in segmental colectomy patients. Anesthesiol 2005, 103: Abst. A893.
53. Azodo, I.A., Ehrenpreis, E.D. Alvimopan (Adolor/GlaxoSmithKline). Curr Opin Investig Drugs 2002, 3: 1496-501.
54. Cassel, J.A., Daubert, J.D., DeHaven, R.N. [(3)H]Alvimopan binding to the micro opioid receptor: Comparative binding kinetics of opioid antagonists. Eur J Pharmacol 2005, 520: 29-36.
55. Udeh, E., Goldman, M. Alvimopan: A peripherally selective opioid mu receptor antagonist. Formulary 2005, 40: 176-83.
56. Foss, J., Marbury, T., Melikian, A.P., Schmith, V.D., Du, W., Wallin, B. Pharmacokinetics of alvimopan, a novel, oral, peripherally acting mu-opioid receptor (PAM-OR) antagonist, and its primary metabolite in the elderly. Pharmacother 2005, 25: 1505, Abst. 0325.
57. Foss, J.F., Schmith, V.D., Wallin, B.A., Du, W., Melikian, A.P., Hillerud, A. Alvimopan (Entereg™), a novel opioid antagonist, achieves active systemic concentrations. Clin Pharmacol Ther 2005, 77: P74, Abst. PII-90.
58. Foss, J., Schmith, V., Fort, J., Du, W., Techner, L. Pharmacokinetics of alvimopan and its amide hydrolysis metabolite: Effect of perioperative antibiotic use in patients undergoing laparotomy. American College of Clinical Pharmacy, St. Louis 2006, Poster 245.
59. Schmidt, W.K. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 2001, 182: 27S-38.
60. Paulson, D.M., Kennedy, D.T., Donovick, R.A. et al. Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J Pain 2005, 6: 184-92.
61. ClinicalTrials.gov. Alvimopan for the treatment of constipation due to opioids being taken for persistent non-cancer pain. Available at: http://clinicaltrials.gov/ct/show/NCT00259922?order=1. Accessed December 7, 2006.
62. ClinicalTrials.gov. Treatment of constipation due to opioids being taken for persistent non-cancer pain. Available at: http://www. clinicaltrials.gov. Accessed: December 7, 2006.
63. Taguchi, A., Sharma, N., Saleem, R.M. et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 2001, 345: 935-40.
64. Panchal, S., Foss, J., Techner, L. et al. Safety and tolerability of alvimopan in healthy volunteers following opioid withdrawal. J Pain 2005, 6: S41, Abst. 730.
65. Senagore, A.J., Kraft, M., Du, W., Fort, J.G., Techner, L., Bell, T.J. Alvimopan is associated with a reduction in overall hospital length of stay and a decreased incidence of prolonged length of stay in patients undergoing bowel resection. American Society of Health-System Pharmacists, Anaheim 2006, Poster 206.
66. Viscusi, E.R., Leslie, J.B., Fort, J.G., Du, W., Techner, L. Alvimopan, a novel peripherally acting mu-opioid receptor antagonist, does not affect opioid-based, centrally mediated analgesia. J Pain 2006, 7 (Suppl. S): 42.
67. Wolff, B.G., Weese, J.L., Ludwig, K.A. et al. Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg 2007, 204: 609-16.
68. Delaney, C., Wolff, B., Viscusi, E., Techner, L., Du, W., Wallin, B. Alvimopan, a novel, peripherally active mu opioid receptor antagonist, in postoperative ileus (POI): A pooled analysis of patients undergoing laparotomy. Colorectal Dis 2005, 7 (Suppl. 1): 93. Abst. P147.
69. Foss, J., Marbury, T., Melikian, A.P., Schmith, V.D., Du, W., Wallin, B. Pharmacokinetics and safety of alvimopan, a novel, oral, peripherally acting mu-opioid receptor (PAM-OR) antagonist, in patients with renal impairment. Pharmacotherapy 2005, 25: 1504, Abst. 0324.
70. Braga, M., Vignali, A., Zuliani, W., Frasson, M., Di Serio, C., Di Carlo, V. Laparoscopic versus open colorectal surgery: Cost-benefit analysis in a single-center randomized trial. Ann Surg 2005, 242: 890-5; discussion 895-6.
71. Prasad, M., Matthews, J.B. Deflating postoperative ileus. Gastroenterol 1999, 117: 489-92.
72. Saclarides, T.J. Current choices - good or bad - for the proactive management of postoperative ileus: A surgeon's view. J Perianesth Nurs 2006, 21: S7-15.
73. Senagore, A., Wang, P.F., Saunders, W. et al. Recorded incidence and economic burden associated with postoperative ileus. American Society of Health-System Pharmacists, Orlando 2006, Poster 36E.
74. Oderda, G.M., Said, Q., Evans, R.S. et al. Opioid-related adverse drug events in surgical hospitalizations: Impact on costs and length of stay. Ann Pharmacother 2007, 41: 400-6.